This trial is conducted in Europe. The aim of this trial is to test for bioequivalence between two formulations of Insulatard® in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
44
Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
Unnamed facility
Neuss, Germany
Area under the serum insulin concentration-time curve (AUC 0-24 hours)
Maximum serum insulin concentration (Cmax)
Area under the serum insulin concentration-time curve (AUC 0-inifinity hours)
Time to maximum serum insulin concentration (tmax)
Terminal serum insulin half life (t½)
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.